Basic Information
| LncRNA/CircRNA Name | ANRIL |
| Synonyms | CDKN2B antisense RNA1 |
| Region | GRCh38_9:21994778-22121097 |
| Ensemble | ENSG00000240498 |
| Refseq | NR_003529 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qRT-PCR, Western blot, Luciferase Activity Assay, RIP |
| Sample | SMCC7721, HepG2, MHCC-97H, SNU-449, HUH7, LO2 and HEK-293T cells |
| Expression Pattern | up-regulated |
| Function Description | ANRIL expression was upregulated in HCC cells, in comparison to the normal human liver cells LO2.Knockdown of ANRIL suppressed HCC cell proliferation and induced cell cycle arrest and apoptosis. HCC cell migration and invasion capacity were inhibited by inhibition of ANRIL. Bioinformatics analyses revealed that ANRIL could interact with miR-384. |
| Pubmed ID | 31679275 |
| Year | 2019 |
| Title | Evaluation of LncRNA ANRIL Potential in Hepatic Cancer Progression |
External Links
| Links for ANRIL | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |